Biocon secured US FDA approval for Pebrilzo, a biosimilar of breast cancer drug Perjeta, marking its fifth oncology biosimilar in the US.
Biocon Limited told exchanges on Monday, 16 November, that the regulator had cleared the injection, known generically as pertuzumab-qcay.
A biosimilar is a close copy of an existing biologic medicine, one made from living cells. Perjeta is the original.
Biocon’s filing says Pebrilzo shows no clinically meaningful differences from it in safety, quality or effectiveness.
The drug targets HER2-positive breast cancer, an aggressive form of the disease. It works by blocking HER2 receptors on cancer cells.
Doctors will give it alongside another drug, trastuzumab, and chemotherapy, in both early-stage and metastatic cases.
The label carries warnings about heart problems and harm to unborn babies. Patients need regular heart checks and contraception during treatment.
Biocon says about 320,000 women in the US may be diagnosed with breast cancer in 2026. Around 20% of them will have the HER2-positive type. Patients will wait a while, though.
Biocon has signed a global settlement and licence agreement with Genentech, which sets the earliest licensed US launch in the third quarter of calendar 2028.
Pebrilzo joins four other US-approved oncology biosimilars from Biocon: Ogivri, Jobevne, Fulphila and Aukelso.
In September, a European Medicines Agency committee recommended marketing authorisation for the same drug in Europe under the Pebrilzo name.
That is a recommendation, not a final approval. Chief executive Shreehas Tambe said the burden of this disease goes beyond the physical toll and often strains families financially.
He said the approval advances Biocon’s push to widen access to affordable biologic medicines. More cancer drugs are in the pipeline.
Biocon also has proposed biosimilars of trastuzumab with hyaluronidase, nivolumab and pembrolizumab. For now, Pebrilzo is approved but not yet on sale.
Want a clearer plan for your next intraday trade? Get research-backed recommendations with entry levels, targets, stop-losses and timely updates. Download the Intraday Traders by EquityPandit app and get started.
Live
